Meta Platforms (NASDAQ:META) stock just earned a strong endorsement from UBS, which raised its price target on shares from $872 to $908 while maintaining a Buy rating. The firm’s bull thesis centers on continued GenAI-driven ad revenue growth and expected upward EPS and valuation revisions through 2026. For long-term investors, the revised target signals that ... UBS Hikes Meta Platforms’ Target From $872 to $908: Is the GenAI Ad Revenue Machine Just Warming Up?